Ownership / Tonix Pharmaceuticals Holding Corp. | Tables in SEC filings

TNXP Tonix Pharmaceuticals Holding Corp.

Quarterly report

							Accumulated
					Additional		Other
	Common stock				Paid in		Comprehensive		Accumulated
	Shares		Amount		Capital		Gain (loss)		Deficit		Total
Balance, December 31, 2023		2,077,088	$	2	$	706,413	$	(232)	$	(600,658)	$	105,525
Issuance of common stock upon exercise of prefunded common warrants		470,102		1		(1)		—		—		—
Fair value of warrants reclassified from liabilities to equity		—		—		15,850		—		—		15,850
Employee stock purchase plan		2,074		—		23		—		—		23
Stock-based compensation		—		—		1,692		—		—		1,692
Foreign currency transaction loss		—		—		—		(8)		—		(8)
Net loss		—		—		—		—		(14,939)		(14,939)
Balance, March 31, 2024		2,549,264		3		723,977		(240)		(615,597)		108,143
Issuance of common stock, net of transactional expenses of $1,704		4,369,807		4		10,726		—		—		10,730
Issuance of common stock upon exercise of prefunded common warrants		2,913,516		3		(3)		—		—		—
Fair value of warrants reclassified from equity to liabilities		—		—		(9,977)		—		—		(9,977)
Fair value of warrants reclassified from liabilities to equity		—		—		10,832		—		—		10,832
Stock-based compensation		—		—		1,154		—		—		1,154
Foreign currency transaction loss		—		—		—		(3)		—		(3)
Net loss		—		—		—		—		(78,776)		(78,776)
Balance, June 30, 2024		9,832,587		10		736,709		(243)		(694,373)		42,103
Issuance of common stock, net of transactional expenses of $557		3,393,600		3		3,481		—		—		3,484
Issuance of common stock upon exercise of prefunded common warrants		7,931,298		8		(8)		—		—		—
Issuance of common stock under the At-the-Market agreement, net of transactional expenses of $1,681		134,466,637		135		41,667		—		—		41,802
Employee stock purchase plan		6,927		—		4		—		—		4
Stock-based compensation		—		—		1,038		—		—		1,038
Foreign currency transaction loss		—		—		—		(7)		—		(7)
Net loss		—		—		—		—		(14,213)		(14,213)
Balance, September 30, 2024		155,631,049	$	156	$	782,891	$	(250)	$	(708,586)	$	74,211


	Three months ended September 30,
	2024		2023
Zembrace Symtouch	$	2,485	$	3,292
Tosymra		337		697
Total product revenues	$	2,822	$	3,989

Year Ending December 31,
Remainder of 2024	$	75
2025		299
2026		142
2027		139
2028 and beyond		108
		763
Included interest		(63)
	$	700

	September 30, 2024		December 31, 2023
	(in thousands)
Raw Materials	$	3,346	$	3,611
Work-in-process		1,953		2,539
Finished Goods		2,632		7,489
Total Inventory	$	7,931	$	13,639

Year Ending December 31,
Remainder of 2024	$	75
2025		299
2026		142
2027		139
2028 and beyond		108
		763
Included interest		(63)
	$	700

Table search / Ownership / Tonix Pharmaceuticals Holding Corp.

163 results

Top filers

Top filing types

Recent filing years